Another AZ exec jumps ship for CEO job at smaller drugmaker

AstraZeneca ($AZN) has lost its second top executive in less than two weeks, as VP James Ward-Lilley bids goodbye to Big Pharma to run the respiratory specialist Vectura--which happens to have partnerships with AZ lung-drug rivals GlaxoSmithKline ($GSK) and Novartis ($NVS). Currently head of AZ's portfolio strategy in respiratory, inflammation and autoimmunity, Ward-Lilley will join Vectura Oct. 1. Story | Release

Suggested Articles

AMAG's female libido drug Vyleesi has just won FDA approval. But will it reach blockbuster state? Management and analysts have different opinions.

Roche’s Genentech new innovation targets cancer cells via video game to raise awareness of personalized medicine, tumor types and biomarker testing.

Alexion is undergoing a major makeover by moving away from ultra-rare diseases, but it still has more to pursue in an effort to back up Soliris.